跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ANDEMBRY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ANDEMBRY
Authorized
STANDARD
ANDEMBRY
CSL BEHRING CANADA INC
🇨🇦 Health Canada
Approval Date
Apr 6, 2026
Approval ID
e269b40286b96515
Company
CSL BEHRING CANADA INC
Type
Standard
Approval Details
Approval Id
e269b40286b96515
Drug Approval Canada Name
ANDEMBRY
Product Name
ANDEMBRY
Status
Marketed
Status Date
2025-10-24
Original Market Date
2025-10-24
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
PRESCRIPTION , SCHEDULE D
Ahfs
24:48.12
Atc Original
B06AC07 GARADACIMAB
Aig Number
0167510001
Company Name
CSL BEHRING CANADA INC
Company Address
350 55 Metcalfe Street Ottawa Ontario Canada K1P 6L5
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Apr 6, 2026
Approval ID
e269b40286b96515
Type
Standard
Back to Health Canada Approvals